Amarin Corp Plcuk (AMRN) Non-Current Deffered Revenue (2015 - 2024)
Amarin Corp Plcuk (AMRN) reported Non-Current Deffered Revenue of $2.1 million for Q1 2024, down 83.4% year-over-year from $12.7 million in Q2 2023, and down 15.98% quarter-over-quarter from $2.5 million in Q4 2023.
Amarin Corp Plcuk (AMRN) Non-Current Deffered Revenue (2015 - 2024) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 10 years of Non-Current Deffered Revenue data on file, last reported at $2.1 million in Q1 2024.
- Non-Current Deffered Revenue for Q1 2024 came in at $2.1 million, down 83.4% year-over-year; the trailing twelve-month figure through Mar 2024 was $2.1 million (down 83.4% YoY), and the FY2023 annual result was $2.5 million, down 80.92% from the prior year.
- Non-Current Deffered Revenue retreated to $2.1 million in Q1 2024 per AMRN's latest filing, from $2.5 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $17.5 million in Q1 2020 and troughed at $2.1 million in Q1 2024.
- A 5-year average of $11.6 million and a median of $13.8 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2021 and 2024: Non-Current Deffered Revenue rose 9.75% in 2021, then plunged 83.4% in 2024.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $15.7 million in 2020, then dropped by 10.48% to $14.1 million in 2021, then declined by 6.49% to $13.1 million in 2022, then sank by 80.92% to $2.5 million in 2023, then declined by 15.98% to $2.1 million in 2024.
- Business Quant data shows AMRN's Non-Current Deffered Revenue at $2.1 million in Q1 2024, $2.5 million in Q4 2023, and $2.9 million in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Amarin Corp Plcuk | 6.77 Bn | 6.59 Bn | 17.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 2.11 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Sep 30, 2023 | 2.95 Mn |
| Jun 30, 2023 | 3.33 Mn |
| Mar 31, 2023 | 12.70 Mn |
| Dec 31, 2022 | 13.15 Mn |
| Sep 30, 2022 | 13.50 Mn |
| Jun 30, 2022 | 13.81 Mn |
| Mar 31, 2022 | 14.14 Mn |
| Dec 31, 2021 | 14.06 Mn |
| Sep 30, 2021 | 14.49 Mn |
| Jun 30, 2021 | 14.83 Mn |
| Mar 31, 2021 | 15.20 Mn |
| Dec 31, 2020 | 15.71 Mn |
| Sep 30, 2020 | 13.20 Mn |
| Jun 30, 2020 | 14.51 Mn |
| Mar 31, 2020 | 17.52 Mn |
| Dec 31, 2019 | 18.50 Mn |
| Sep 30, 2019 | 17.62 Mn |
| Jun 30, 2019 | 17.78 Mn |